You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Johnson and Johnson
McKesson
Boehringer Ingelheim

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Famitinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Famitinib?

Famitinib is an investigational drug.

There have been 20 clinical trials for Famitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.

There are eight US patents protecting this investigational drug and sixty-three international patents.

Recent Clinical Trials for Famitinib
TitleSponsorPhase
A Bioequivalence Study of Famitinib Malate on Healthy Chinese VolunteersJiangsu HengRui Medicine Co., Ltd.Phase 1
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Fudan UniversityPhase 2
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid TumorJiangsu HengRui Medicine Co., Ltd.Phase 2

See all Famitinib clinical trials

Clinical Trial Summary for Famitinib

Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib

See all Famitinib clinical trials

US Patents for Famitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Famitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Famitinib Argentina 109919 2036-10-10   Start Trial
Famitinib Australia 2017342022 2036-10-10   Start Trial
Famitinib Brazil 112019007144 2036-10-10   Start Trial
Famitinib Canada 3039760 2036-10-10   Start Trial
Famitinib Chile 2019000941 2036-10-10   Start Trial
Famitinib China 110382494 2036-10-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Baxter
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.